Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis

J Neuroimmunol. 2012 Oct 15;251(1-2):14-24. doi: 10.1016/j.jneuroim.2012.06.005. Epub 2012 Jun 28.


Laquinimod is an orally active molecule that showed efficacy in clinical trials in multiple sclerosis. We studied its effects in the CNS, when administered by therapeutic regimen to mice inflicted with experimental autoimmune encephalomyelitis (EAE). Laquinimod reduced clinical and inflammatory manifestations and elevated the prevalence of T-regulatory cells in the brain. In untreated mice, in the chronic disease stage, brain derived neurotrophic factor (BDNF) expression was impaired. Laquinimod treatment restored BDNF expression to its level in healthy controls. Furthermore, CNS injury, manifested by astrogliosis, demyelination and axonal damages, was significantly reduced following laquinimod treatment, indicating its immunomodulatory and neuroprotective activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Axons / drug effects
  • Brain-Derived Neurotrophic Factor / biosynthesis*
  • Demyelinating Diseases / drug therapy
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy*
  • Encephalomyelitis, Autoimmune, Experimental / metabolism
  • Female
  • Immunologic Factors / therapeutic use*
  • Mice
  • Mice, Inbred C57BL
  • Multiple Sclerosis / drug therapy
  • Neuroprotective Agents / therapeutic use*
  • Quinolones / therapeutic use*
  • T-Lymphocytes, Regulatory / drug effects*


  • Brain-Derived Neurotrophic Factor
  • Immunologic Factors
  • Neuroprotective Agents
  • Quinolones
  • laquinimod